Skip to main content
. 2024 Jul 24;48:102060. doi: 10.1016/j.tranon.2024.102060

Fig. 3.

Fig 3

RFS and OS of PC-naïve (HrR+/HER2−) and NAC (HrR+/HER2−) cohort

RFS (A) and OS (B) stratified according to cohort; RFS (C) and OS (D) stratified according to cohort and TP53 signature status. RFS (E) and OS (F) stratified according to cohort and TP53 signature status, excluding cases with pCR from the NAC (HrR+/HER2−) cohort.

RFS, recurrence-free survival; OS, overall survival; PC-naïve, perioperative chemotherapy-naïve; HrR, hormone receptor; HER2, human epidermal growth factor receptor type 2; NAC, neoadjuvant chemotherapy; pCR, pathological complete response; wt, wild-type signature, mt, mutant signature; HR, hazard ratio; CI: confidence interval.